AOD-9604 is the textbook case of a peptide that failed its pivotal weight-loss trial more than a decade ago and still gets sold to consumers — partly because Australia briefly reclassified it as a supplement, partly because compounding pharmacies in the GLP-1 shortage era picked it back up. The compound originated at Monash University in the 1990s as a modified fragment of human growth hormone, licensed to Metabolic Pharmaceuticals, and taken through clinical development with genuine scientific optimism. Then a Phase 2b randomized controlled trial in overweight and obese adults found no statistically significant weight loss versus placebo at 24 weeks. The honest answer to whether AOD-9604 works for fat loss is: the only large RCT that tested that question said no.
Summary / Quick Answer: What Is AOD-9604 and Does It Work?
AOD-9604 is a synthetic peptide derived from amino acids 177-191 of human growth hormone, modified with a tyrosine extension at the N-terminus. In animal models it consistently promoted fat metabolism. In the only Phase 2b trial conducted in humans, it failed to achieve statistical separation from placebo on body weight at 24 weeks.
Best for: Researchers and clinicians tracking the gap between promising animal data and clinical reality in obesity pharmacology.
Not ideal for: Anyone seeking a proven, legally obtainable fat-loss treatment. It is NOT FDA-approved as a drug. It is sold in the United States as a "research peptide" or through compounding pharmacies, with no regulatory endorsement of efficacy.
What to look for: If a vendor or clinic claims AOD-9604 "has clinical evidence for weight loss," ask for the specific trial result on the primary endpoint. The Phase 2b answer is publicly available and not favorable.
Decision shortcut: If you are considering AOD-9604 specifically because it sounds like a safer growth hormone alternative, know that the safety profile across the clinical program appeared acceptable — but safety and efficacy are different questions. A compound can be well-tolerated and still not work. AOD-9604 is that compound.
What AOD-9604 Actually Is
AOD-9604 stands for Anti-Obesity Drug 9604, the internal designation given to it during its development phase. The foundation is the C-terminal region of human growth hormone (hGH), specifically the stretch of amino acids running from position 177 to 191. Researchers at Monash University in Melbourne identified this region in the early 1990s as the domain responsible for growth hormone's fat-metabolism effects, separate from the N-terminal portion that drives IGF-1-mediated anabolic signaling.
That distinction mattered. Intact hGH administered pharmacologically promotes fat breakdown but also causes insulin resistance and a range of side effects tied to its growth-promoting, IGF-1-elevating activity. If you could isolate the lipolytic function in a fragment, the theory went, you might get targeted fat metabolism without the metabolic penalties. The first versions of this compound, referred to in early literature as hGH 177-191 or AOD9401, were tested in rodent models through the late 1990s and early 2000s.
The final formulation — AOD-9604 — added a tyrosine residue at the N-terminus to improve the peptide's stability and behavior. It is not the same as the "HGH Fragment 176-191" sold on many grey-market sites, which lacks that tyrosine addition and has slightly different numbering. The distinction is meaningful both chemically and for interpreting research, because most of the clinical development data applies specifically to AOD-9604, not to the more widely available grey-market variant.
You can read more about what peptides are and how they are classified if the terminology here is new, or review the general safety questions that apply across grey-market peptides before going further.
The Animal Evidence That Made It Seem Promising
The preclinical case for AOD-9604 was not trivial. Across several rodent studies published between 1994 and 2000, the hGH 177-191 fragment and its close variants consistently reduced adipose tissue mass, inhibited lipogenesis, and increased lipolytic activity in obese mouse and rat models.
A 1994 study by Natera, Jiang, and Ng (PMID 7987248) demonstrated that chronic treatment with synthetic hGH 177-191 reduced cumulative body weight gain and decreased adipose tissue mass in obese mice, while significantly inhibiting lipogenesis in adipose tissue. The researchers concluded it represented the functional antilipogenic domain of the intact growth hormone molecule.
A 2000 study in the American Journal of Physiology by Heffernan et al. (PMID 10950816) extended this to oral administration. Obese mice treated with AOD-9401 showed significantly lower body weight gain from day 16 onward, reduced lipogenic activity, and an acute increase in energy expenditure and glucose oxidation. The compound also demonstrated lipolytic activity in isolated human adipose tissue — an in vitro signal that made it seem relevant to human biology.
A separate 2000 study in the Journal of Molecular Endocrinology by Ng et al. (PMID 11116208) reported that AOD9401 stimulated hormone-sensitive lipase and inhibited acetyl coenzyme A carboxylase in isolated rat adipose tissue. After 20 days, adipocyte diameter fell from 110 to 80 micrometers. Critically, unlike intact growth hormone, the fragment did not induce insulin resistance or glucose intolerance — reinforcing the case for a cleaner, more targeted metabolic tool. Earlier work from 1993 (PMID 8118430) had shown the fragment reduced glucose uptake in obese-rat adipocytes with greater antilipogenic potency than intact growth hormone.
These were consistent, reproducible results in rodent systems. The translation to humans looked scientifically reasonable. The problem is that looking scientifically reasonable and being clinically effective are two separate claims — and pharmaceutical history is full of compounds that bridged animal models beautifully and then collapsed in human trials.
The Phase 2b Failure That Should Have Ended It
Metabolic Pharmaceuticals, the Australian biotech that licensed AOD-9604, ran a clinical development program through the 2000s that included multiple Phase 1 and Phase 2 studies assessing safety and early dose-finding. A meta-analysis of six randomized controlled trials examining safety found that AOD-9604 did not affect serum IGF-1 levels — consistent with the animal data showing separation from the growth-promoting axis. The compound appeared well-tolerated across these early-phase studies.
The decisive test was a Phase 2b randomized, double-blind, placebo-controlled trial in overweight and obese adults. It ran for 24 weeks across multiple dose arms, designed to demonstrate meaningful body weight reduction relative to placebo. Phase 2b is the gateway test: pass it and you earn Phase 3; fail it and development typically stops.
AOD-9604 failed. The trial found no statistically significant difference in body weight loss between AOD-9604 and placebo at 24 weeks. The compound that had reliably shrunk adipocytes in rats did not move the scale in adult humans beyond what placebo achieved. Metabolic Pharmaceuticals did not advance AOD-9604 into Phase 3, and development for the obesity indication was discontinued.
This is not a minor footnote. This is the central clinical fact about AOD-9604. The compound failed the exact study designed to determine whether it works for the exact purpose it is marketed for today.
How a Failed Drug Became a "Research Peptide" Again
Here is where the regulatory and commercial story gets complicated — and where the honest accounting matters most.
After the Phase 2b failure, AOD-9604 did not simply disappear. In 2014, the Australian Therapeutic Goods Administration briefly reclassified AOD-9604 from a regulated drug to Schedule 4 (prescription medicine) and in some interpretations to a supplement category, based on an assessment that its safety profile was acceptable. The reclassification was specifically about regulatory scheduling and did not constitute an endorsement of efficacy. The TGA has since updated its stance, and the compound does not hold an approved drug or therapeutic indication in Australia.
The brief Australian reclassification created an opening that grey-market operators used extensively. If it had been reclassified as a supplement, the marketing logic went, it must be safe and legal to sell — a category confusion that collapsed the distinction between "not acutely dangerous" and "proven to work." This narrative spread across online forums and bodybuilding communities, severed from the inconvenient Phase 2b result.
The second wave of AOD-9604 attention arrived during the 2022 to 2024 GLP-1 receptor agonist shortage. When semaglutide and tirzepatide became difficult to obtain through normal channels, some compounding pharmacies began building weight-loss stacks that included AOD-9604 alongside other peptides and compounds. AOD-9604 is NOT FDA-approved as a drug in the United States. It is sold as a "research peptide" by grey-market vendors and appears in some compounded formulations under the 503A patient-specific compounding framework, though its regulatory eligibility under that pathway is contested. The FDA has taken enforcement actions against compounders marketing unapproved peptides, and AOD-9604 is in a genuinely ambiguous legal category that can shift with regulatory updates.
For consumers who encountered AOD-9604 stacked with other weight-loss compounds during this period, sorting out which compound did what — if anything — is impossible. The context these consumers usually lack is the Phase 2b failure sitting quietly in the clinical record.
Regulatory Status: US and Australia
United States. AOD-9604 is NOT approved by the FDA as a drug for any indication. It does not appear on the FDA's list of bulk drug substances evaluated for compounding. It exists in a grey zone where research chemical suppliers sell it and some compounding pharmacies include it in prepared formulations — practices that carry legal risk for compounders and uncertain status for end users. The FDA has signaled increased scrutiny of unapproved peptides in compounding contexts, and this landscape can change with little public notice.
Australia. The compound was developed there, and the TGA briefly reclassified it in 2014, which created the supplement-adjacent impression described above. As of 2025, AOD-9604 does not hold an approved therapeutic indication in Australia. Current scheduling status should be verified directly against the TGA database — this article is not legal or regulatory advice.
Research peptide designation. The "research peptide" label is not an FDA or TGA category. It is a commercial term used to position compounds outside the regulatory perimeter for drug products by claiming they are sold only for laboratory use. The designation offers vendors legal cover but provides consumers with no quality assurance, dosing verification, or product consistency guarantee.
Safety and Grey-Market Reality
The safety signal from AOD-9604's clinical program is one of its more defensible aspects. A meta-analysis of six early-phase RCTs found no significant effect on IGF-1 levels, and early trials did not identify alarming adverse event patterns. But "well-tolerated in Phase 1 and Phase 2a studies" is a very different statement from "safe for long-term use in a general population buying injectable compounds from unregulated sources."
Product quality is unverified. Research peptides are not subject to pharmaceutical manufacturing standards, third-party purity testing, or dosing verification. Contamination, incorrect concentration, and misidentified compounds are documented risks across the grey-market peptide space.
Injection risk is real. AOD-9604 is typically administered subcutaneously. Injection-site infections, abscess formation, and bloodborne pathogen exposure are practical concerns for anyone self-injecting without clinical supervision.
Drug interactions are untested. No safety data exists for AOD-9604 combined with GLP-1 receptor agonists, metformin, or other widely used metabolic drugs.
Pregnancy and nursing. No safety data exists for either context. Avoid it entirely.
The most useful diagnostic question for any vendor or clinic promoting AOD-9604 is: what do they say about the Phase 2b result? If they do not mention it, or frame the clinical record as "promising early data," they are misrepresenting what exists. A compound that completed Phase 2b and failed is not in early-stage development — it is in discontinued development for that indication.
Frequently Asked Questions
Is AOD-9604 the same as HGH Fragment 176-191?
No. They share the same C-terminal hGH region but are not identical. AOD-9604 includes a tyrosine residue at the N-terminus (producing the modified 177-191 fragment), which affects its stability. The grey-market compound sold as "HGH Frag 176-191" lacks this modification. Most clinical development data applies specifically to AOD-9604. Claims about one do not automatically transfer to the other.
Did AOD-9604 work in any clinical trials?
Early-phase studies (Phase 1 and Phase 2a) assessed safety and tolerability, not weight-loss efficacy. AOD-9604 failed its Phase 2b weight-loss efficacy endpoint versus placebo at 24 weeks — the study specifically designed to answer whether it works for obesity.
Why do some people report losing weight on AOD-9604?
Several explanations are more plausible than a true drug effect: placebo response (typically 1-3 kg in weight-loss trials), simultaneous diet and lifestyle changes, other compounds in stacked protocols, and regression to the mean. Anecdotal reports do not substitute for randomized controlled trial results on an outcome as susceptible to confounding as body weight.
What is the difference between a failed clinical trial and no clinical trials?
Compounds that have never been tested in large human trials simply lack evidence. AOD-9604 was tested at Phase 2b scale — and the evidence said it did not outperform placebo. These are meaningfully different evidentiary positions. The former is an absence of data; the latter is a negative result.
Conclusion
AOD-9604 presents a pattern common in peptide marketing: animal data that is genuinely interesting, clinical trials that failed to replicate those effects at scale, a regulatory event that created ambiguous consumer signals, and a commercial ecosystem that sells the animal data while quietly omitting the Phase 2b result.
The actionable takeaway is straightforward. If you are considering AOD-9604 for weight loss, know that it failed Phase 2b — the pivotal human efficacy test — more than a decade ago, that it is NOT FDA-approved as a drug, and that the "research peptide" or compounded-preparation route offers no quality or dosing assurance. The compounds that have actually cleared large randomized controlled trials for weight loss are GLP-1 receptor agonists with known safety profiles. Reviewing the broader peptide evidence base for weight loss is a useful orientation before evaluating specific options, and understanding why peptide safety questions are harder to answer than they look is the foundation for any decision in this space.
AOD-9604 was a scientifically reasonable hypothesis that did not survive contact with a rigorous trial. That outcome is not a reason to keep looking for a workaround — it is the conclusion.
This article is for informational and educational purposes only. It does not constitute medical advice, and nothing here should be interpreted as a recommendation to use AOD-9604 or any other peptide compound. AOD-9604 is not approved by the FDA for any indication. Consult a licensed healthcare provider before making any decisions about weight-loss interventions or prescription compounds. If you are pregnant, nursing, or have any underlying health condition, do not use experimental or unapproved compounds.
This article is for informational purposes and not medical advice. Peptides, especially those marketed for therapeutic use, can interact with medications and health conditions. Consult a licensed physician before starting any supplement, particularly if you are pregnant, nursing, taking prescription medications, or managing a chronic condition.
